ClinicalTrials.gg
CompletedNCT00149890Updated Sep 22, 2011Results posted

Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids

A Phase 3 interventional study of Basiliximab and Cyclosporine/cyclosporine microemulsion in Liver Transplantation and Infection, sponsored by Novartis. Completed at 1 site in Germany. Open to participants aged Up to 16 Years. Per ClinicalTrials.gov, last updated 2011-09-22.

Sponsored by Novartis · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
Up to 16 Years
Sex
All
01

Study summary

Systemic infection is still a major concern in young children with liver transplantation. The approach of this study is to reduce the risk of systemic infections by avoiding intraoperative steroids (another class of immunosuppressive drugs) given in combination with basiliximab, cyclosporine and steroids in pediatric de novo liver transplant recipients. The treatment is compared to the same treatment regimen including intraoperative steroids with respect to rejection episodes.

02

Conditions studied

  • Liver Transplantation
  • Infection

Browse trials for

Keywords

  • pediatric
  • liver transplantation
  • Simulect
  • Basiliximab
  • ciclosporin microemulsion
  • steroid reduction
  • pediatric liver transplantation
03

In context

Infections

2,097 studies on the registry are indexed under Infections; 361 are open to participants now.

This study's enrollment of 77 is below the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric patients undergoing primary orthotopic liver transplantation (whole organ or split liver or reduced size)
  • Cadaveric or living donor (related or unrelated)

Exclusion criteria

Exclusion Criteria:

  • Patients who are recipients of multiple solid organ transplants and/or who have previously received transplanted organs
  • If cold ischemia time of the transplanted organ is >12 hours
  • Auxiliary liver transplant recipients
  • Fulminant hepatic failure
  • hepatitis
  • Primary sclerosing cholangitis
  • Severe acute systemic infections
  • surface antigen// positive
  • Known to intravenous (i.v.) or per os (orally) (p.o.) cyclosporine or corticoids
  • Non-ability to comply with the protocol
  • Relevant abnormal physical or laboratory findings within 2 weeks of inclusion
  • Relevant severe allergy, to basiliximab or similar drugs
  • History/presence of relevant
  • Pregnancy/breastfeeding
  • Use of any or immunomodulatory/ drug within 4 weeks prior to transplantation.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    With Intraoperative Steroids

    Intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was \<35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab was administered as an intravenous bolus injection within 8 hours after reperfusion of the graft.

    Drug: Basiliximab · Drug: Cyclosporine/cyclosporine microemulsion · Drug: Steroid

  • Active comparator
    Without Intraoperative Steroids

    No intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was \<35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab and the first dose of steroids had to be administered within 8 hours after reperfusion of the graft and basiliximab was given as an intravenous bolus injection.

    Drug: Basiliximab · Drug: Cyclosporine/cyclosporine microemulsion · Drug: Steroid

Interventions

  • Basiliximab (10 mg) was supplied as a lyophilisate in vials with ampoules of sterile water for injection (5 mL) and had to be given of 10 mg (body weight \<35 kg) or 20 mg (body weight ≥35 kg) strength.

    Also known as: Simulect®

  • DrugCyclosporine/cyclosporine microemulsion

    Drug page: Cyclosporine

    Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as per center practice. During the 6 months treatment period Cyclosporine doses had to be adjusted according to Cyclosporine A (CsA)-trough levels.

    Also known as: Sandimmun®/Sandimmun® Optoral

  • Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0). The first dose of steroids in treatment arm 2 (day 0) had to be administered within 8 hours after reperfusion of the graft. Beginning from day 1 to day 6 doses of 15 mg/m2/day had to be given intravenously (i.v.) in both treatment arms. Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally (until end of month 2), to 2.5 mg/m²/day orally (until end of month 3) and to 1 mg/m²/day orally (until end of month 6).

06

What researchers measure

Primary outcomes

  1. Number of Participants With at Least One Biopsy Proven Acute Rejection (BPAR) Episode, Graft Loss or Death Within the First Three Months Post-transplantation

    Graft loss is defined as being listed for a re-transplantation. The analysis was based on the locally performed biopsy assessments. Generally, patients not experiencing a relevant event (i.e., acute rejection, graft loss or death) were censored with the last visit date.

    Time frame: 3 months after treatment

Secondary outcomes

  1. Number of Participants With Biopsy Proven Acute Rejection (BPAR) Episodes Within the First Three Months

    At biopsy of transplanted tissue sample, acute rejection has an onset 2-60 days after transplantation, with interstitial vascular endothelial cell swelling, interstitial accumulation of lymphocytes, plasma cells, immunoblasts, macrophages, neutrophils; tubular separation with edema/necrosis of tubular epithelium; swelling and vacuolization of the endothelial cells, vascular edema, bleeding and inflammation. Clinical signs and symptoms include malaise, fever, and hypertension.

    Time frame: 3 months

  2. Number of Participants With Steroid Resistant Rejection Episodes Within Three and Six Months

    To evaluate the efficacy of a regimen with intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids as measured by the incidence of steroid resistant rejection episodes within three and six months.

    Time frame: 3 and 6 months

  3. Percentage of Participants Experiencing Death or Graft Loss Within Three and Six Months After Transplantation

    Graft loss is defined as being listed for a re-transplantation.

    Time frame: 3 months and 6 months

  4. Number of Participants With Bacterial, Viral and Fungal Infections During Six Months

    To evaluate the safety of a regimen with intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids as measured by the episodes of bacterial, viral and fungal infections during six months.

    Time frame: 6 months

  5. Time of Onset of a First Biopsy Proven Acute Rejection

    Biopsied Tissue shows rejection at onset 2-60 days after transplantation, with interstitial vascular endothelial cell swelling, interstitial accumulation of lymphocytes, plasma cells, immunoblasts, macrophages, neutrophils; tubular separation with edema/necrosis of tubular epithelium; swelling and vacuolization of the endothelial cells, vascular edema, bleeding and inflammation. Clinical signs and symptoms include malaise, fever and hypertension .

    Time frame: 6 months

  6. Percentage of Participants With Treatment Failure Within Three and Six Months

    To evaluate the proportion of patients with treatment failure treated with a therapy consisting of intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids within three and six months.

    Time frame: 3 and 6 months

07

Results

Posted Sep 22, 2011

Participant flow

Participant flow — Overall Study
MilestoneWith Intraoperative SteroidsWithout Intraoperative Steroids
Started3938
Completed2620
Not completed1318
Withdrew: Adverse event18
Withdrew: Lack of efficacy89
Withdrew: Protocol violation10
Withdrew: Lost to follow-up10
Withdrew: Graft loss21

Outcome measures

PrimaryNumber of Participants With at Least One Biopsy Proven Acute Rejection (BPAR) Episode, Graft Loss or Death Within the First Three Months Post-transplantation

Graft loss is defined as being listed for a re-transplantation. The analysis was based on the locally performed biopsy assessments. Generally, patients not experiencing a relevant event (i.e., acute rejection, graft loss or death) were censored with the last visit date.

Time frame:
3 months after treatment
Reported as:
Number · Participants
Number of Participants With at Least One Biopsy Proven Acute Rejection (BPAR) Episode, Graft Loss or Death Within the First Three Months Post-transplantation
ParticipantsWith Intraoperative SteroidsWithout Intraoperative Steroids
Stratum age < 2 years (N=21, 24)815
Stratum age 2-16 years (N=18, 14)1411
Total (N= 39, 38)2226
SecondaryNumber of Participants With Biopsy Proven Acute Rejection (BPAR) Episodes Within the First Three Months

At biopsy of transplanted tissue sample, acute rejection has an onset 2-60 days after transplantation, with interstitial vascular endothelial cell swelling, interstitial accumulation of lymphocytes, plasma cells, immunoblasts, macrophages, neutrophils; tubular separation with edema/necrosis of tubular epithelium; swelling and vacuolization of the endothelial cells, vascular edema, bleeding and inflammation. Clinical signs and symptoms include malaise, fever, and hypertension.

Time frame:
3 months
Reported as:
Number · Participants
Number of Participants With Biopsy Proven Acute Rejection (BPAR) Episodes Within the First Three Months
ParticipantsWith Intraoperative SteroidsWithout Intraoperative Steroids
Number of Participants With Biopsy Proven Acute Rejection (BPAR) Episodes Within the First Three Months2026
SecondaryNumber of Participants With Steroid Resistant Rejection Episodes Within Three and Six Months

To evaluate the efficacy of a regimen with intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids as measured by the incidence of steroid resistant rejection episodes within three and six months.

Time frame:
3 and 6 months
Reported as:
Number · Participants
Number of Participants With Steroid Resistant Rejection Episodes Within Three and Six Months
ParticipantsWith Intraoperative SteroidsWithout Intraoperative Steroids
Within 3 months post treatment22
Within 6 months post treatment22
SecondaryPercentage of Participants Experiencing Death or Graft Loss Within Three and Six Months After Transplantation

Graft loss is defined as being listed for a re-transplantation.

Time frame:
3 months and 6 months
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing Death or Graft Loss Within Three and Six Months After Transplantation
Percentage of participantsWith Intraoperative SteroidsWithout Intraoperative Steroids
Death within 3 months post treatment0.02.6
Death within 6 months post treatment0.02.6
Graft Loss within 3 months post treatment5.12.6
Graft Loss within 6 months post treatment5.15.3
SecondaryNumber of Participants With Bacterial, Viral and Fungal Infections During Six Months

To evaluate the safety of a regimen with intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids as measured by the episodes of bacterial, viral and fungal infections during six months.

Time frame:
6 months
Reported as:
Number · Participants
Number of Participants With Bacterial, Viral and Fungal Infections During Six Months
ParticipantsWith Intraoperative SteroidsWithout Intraoperative Steroids
Fungal1616
Viral1514
Bacterial1018
SecondaryTime of Onset of a First Biopsy Proven Acute Rejection

Biopsied Tissue shows rejection at onset 2-60 days after transplantation, with interstitial vascular endothelial cell swelling, interstitial accumulation of lymphocytes, plasma cells, immunoblasts, macrophages, neutrophils; tubular separation with edema/necrosis of tubular epithelium; swelling and vacuolization of the endothelial cells, vascular edema, bleeding and inflammation. Clinical signs and symptoms include malaise, fever and hypertension .

Time frame:
6 months
Reported as:
Median · Months
Time of Onset of a First Biopsy Proven Acute Rejection
MonthsWith Intraoperative SteroidsWithout Intraoperative Steroids
Time of Onset of a First Biopsy Proven Acute Rejection1.93 (0.89 to NA)0.75 (0.49 to 1.31)
SecondaryPercentage of Participants With Treatment Failure Within Three and Six Months

To evaluate the proportion of patients with treatment failure treated with a therapy consisting of intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids within three and six months.

Time frame:
3 and 6 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Failure Within Three and Six Months
Percentage of participantsWith Intraoperative SteroidsWithout Intraoperative Steroids
3 month: Age < 2 years (N= 21, 24)0.00 (0.00 to 16.11)4.17 (0.11 to 21.12)
3 month: Age 2-16 years (N= 18, 14)11.11 (1.38 to 34.71)7.14 (0.18 to 33.87)
3 Month: Total5.13 (0.63 to 17.32)5.26 (0.64 to 17.75)
6 month: Age < 2 years (N= 21, 24)0.00 (0.00 to 16.11)4.17 (0.11 to 21.12)
6 month: Age 2-16 years (N= 18, 14)11.11 (1.38 to 34.71)7.14 (0.18 to 33.87)
6 Month: Total5.13 (0.63 to 17.32)5.26 (0.64 to 17.75)

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
With Intraoperative Steroids—18/39 (46.2%)39/39 (100%)
Without Intraoperative Steroids—23/38 (60.5%)38/38 (100%)
Most frequent serious events
Showing 10 of 96
Most frequent serious events
EventWith Intraoperative SteroidsWithout Intraoperative Steroids
Post procedural bile leakInjury, poisoning and procedural complications0/395/38
Cytomegalovirus infectionInfections and infestations5/390/38
GastroenteritisInfections and infestations2/393/38
Complications of transplanted liverInjury, poisoning and procedural complications3/392/38
Biliary dilatationHepatobiliary disorders0/392/38
BilomaHepatobiliary disorders0/392/38
CholangitisHepatobiliary disorders2/392/38
Gastroenteritis norovirusInfections and infestations0/392/38
Gastrointestinal anastomotic leakInjury, poisoning and procedural complications0/392/38
Pleural effusionRespiratory, thoracic and mediastinal disorders0/392/38
Most frequent other events
Showing 10 of 108
Most frequent other events
EventWith Intraoperative SteroidsWithout Intraoperative Steroids
HypertensionVascular disorders29/3927/38
PyrexiaGeneral disorders19/3925/38
Pleural effusionRespiratory, thoracic and mediastinal disorders18/3924/38
HypomagnesaemiaMetabolism and nutrition disorders21/3915/38
FlatulenceGastrointestinal disorders20/3916/38
AnaemiaBlood and lymphatic system disorders17/3917/38
ConstipationGastrointestinal disorders15/3917/38
Antithrombin iii decreasedInvestigations16/3916/38
VomitingGastrointestinal disorders10/3915/38
HyperglycaemiaMetabolism and nutrition disorders8/3915/38

Baseline characteristics

Age Continuous
Age Continuous(years)With Intraoperative SteroidsWithout Intraoperative SteroidsTotal
Mean3.08 ± 4.093.71 ± 5.363.39 ± 4.74
Age, Customized
Age, Customized(participants)With Intraoperative SteroidsWithout Intraoperative SteroidsTotal
<2 years212445
from 2 to 16 years181432
Sex: Female, Male
Sex: Female, Male(Participants)With Intraoperative SteroidsWithout Intraoperative SteroidsTotal
Female211940
Male181937
08

Study locations

1 site
  • Novartis Investigational Site
    Various Cities, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2005
First posted
Sep 8, 2005
Start
Mar 2004
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Sep 22, 2011
Last update
Sep 22, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00149890
Lead sponsor
Novartis
First posted
Sep 8, 2005
Start date
Mar 2004
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Sep 22, 2011
Last update
Sep 22, 2011

Study contacts

Novartis
study director · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Basiliximab · Cyclosporine

Start the discussion